Symptoms and Clinical Course of Epilepsy with Myoclonic Absences

DOI 15 References
  • Ikeda Hiroko
    Department of Pediatrics, National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders
  • Fujiwara Tateki
    Department of Pediatrics, National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders
  • Shigematsu Hideo
    Department of Pediatrics, National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders
  • Imai Katsumi
    Department of Pediatrics, National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders
  • Kubota Hidemoto
    Department of Pediatrics, National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders
  • Kubota Yuko
    Department of Pediatrics, National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders
  • Takahashi Yukitoshi
    Department of Pediatrics, National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders
  • Inoue Yushi
    Department of Psychiatry, National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders

Bibliographic Information

Other Title
  • ミオクロニー欠神てんかんの臨床症状と経過

Search this article

Description

  There is no comprehensive study so far in Japan on epilepsy with myoclonic absences (EMA), characterized by myoclonic absences (MA) as a specific seizure type. We retrospectively studied 9 patients (4 males and 5 females) with EMA confirmed by ictal video EEG and polygraph (EEG+EMG) recordings. The age at MA onset ranged from 18 to 92 months and the age at the last follow-up ranged from 3 to 39 years. The patients had IQ of 40 to 79. Eight patients had been free from seizures for more than one year at the last follow up. MA was controlled by valproate sodium monotherapy or combination of valproate sodium and ethosuximide with appropriate plasma levels. Generalized tonic clonic seizures and severe mental retardation were not necessarily associated with poor seizure outcome. Patients with long MA duration or MA status epilepticus were prone to be refractory to medication. EMA can be divided into two subgroups based on the seizure outcome, favorable and unfavorable. Further large-scale study is required.

Journal

  • NO TO HATTATSU

    NO TO HATTATSU 43 (1), 14-18, 2011

    The Japanese Society of Child Neurology

References(15)*help

See more

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top